EPISODE · Oct 1, 2025 · 7 MIN
#047 $CYTK’s Approval Delay The Biotech Oversight That Rocked Investors
from SueWallSt · host SueWallSt
Did $CYTK gamble with the FDA and lose investor trust? In this episode of Sue Wall Street, we unpack the class action lawsuit against Cytokinetics Inc. Despite strong Phase 3 results, the company skipped a critical REMS in their NDA, delaying drug approval and tanking their stock. If you're into biotech moves, FDA filings, or securities law drama, this deep dive is for you. Learn how one missing document may cost shareholders millions. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.
What this episode covers
Did $CYTK gamble with the FDA and lose investor trust? In this episode of Sue Wall Street, we unpack the class action lawsuit against Cytokinetics Inc. Despite strong Phase 3 results, the company skipped a critical REMS in their NDA, delaying drug approval and tanking their stock. If you're into biotech moves, FDA filings, or securities law drama, this deep dive is for you. Learn how one missing document may cost shareholders millions. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.
NOW PLAYING
#047 $CYTK’s Approval Delay The Biotech Oversight That Rocked Investors
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.